NCT03969004 2026-03-27Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell CarcinomaRegeneron PharmaceuticalsPhase 3 Active not recruiting415 enrolled 1 FDA